Fevipiprant

Fevipiprant is a prostaglandin D2 (PGD2) receptor antagonist with a Kd value of 1.14 nM for CRTH2/DP2. It has been shown to inhibit PGD2-stimulated human eosinophil shape change in whole blood assays (IC₅₀ = 0.44 nM) and to inhibit PGD2-induced cytokine release in human Th2 cells (IC₅₀s = 2.56 and 1.4 nM for IL-5 and IL-13, respectively). This compound has undergone testing in a phase II clinical study in uncontrolled allergic asthma.